Find clinical trials for Regeneron Pharmaceuticals. Search for Regeneron Pharmaceuticals clinical trials in different cities and states across the United States.
Filter
Filter results
Results: 57
Active & Responsive
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
for
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF),
Location: Boston MA, New York NY, Orlando FL, Jacksonville FL,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 0 - 17
Code: NCT05788536
Phase1, Phase2, Recruiting
New
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
for
Venous Thromboembolism (VTE)
Location: Hialeah FL, El Paso TX
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07493304
Phase3, Recruiting
New
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
for
Diffuse Large B-cell Lymphoma (DLBCL)
Location: Boston MA, Stony Brook NY, New Brunswick NJ,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06091865
Phase3, Recruiting
New
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
for
Peripheral Artery Disease (PAD)
Location: Amarillo TX
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07318610
Phase3, Recruiting
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
for
Paroxysmal Nocturnal Hemoglobinuria
Location: Toronto
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT05744921
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
for
Relapsed Refractory Multiple Myeloma (RRMM)
Location: Durham NC
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT05730036
Phase3, Recruiting
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
for
Adverse Pregnancy Outcomes, Atopic Dermatitis
Location: Boston MA
Sponsor: Regeneron Pharmaceuticals
Sex: Female
Age: 18 - 49
Code: NCT03936335
Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
for
Monoclonal Gammopathy of Undetermined Significance (MGUS),
Location: Boston MA, Stony Brook NY, Philadelphia PA,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06140524
Phase2, Recruiting
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: New York NY, Tampa FL, Columbus OH, Atlanta GA,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03761108
Phase1, Phase2, Recruiting
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers